A method of treating episodic and chronic nasal congestion of the human nasal passages is disclosed. The present invention combines use of decongestant nasal spray, saline nasal spray, and nasal dilator therapies with minimized risk of incurring rebound congestion. The method may be used as both preventative and withdrawal therapies for patients experiencing rebound congestion. Nasal dilators, decongestant nasal spray and saline nasal spray are provided in kit form whereby users may practice the method.

The present invention provides an edible composition for alleviating visual fatigue. The composition comprises in parts by weight 1 to 10 parts of curcuma powder, 1 to 12 parts of whole coffee fruit extract, 1 to 20 parts of phospholipid composite, 1 to 15 parts of DHA, 0.5 to 5 parts of phosphatidylserine, and 0.1 to 5 parts of vitamin C. After one week of trial consumption by the subject, the duration of photopic vision is improved with a significant difference in comparison with that before the trial; after 2 weeks of trial consumption, the overall score of visual fatigue symptoms decreases with a significant difference in comparison with that before the trial; after 8 weeks of trial consumption by the subject, the vision field thereof is remarkably enlarged, indicating the formulation may prevent the occurrence of glaucoma. The coffee extract combined with the remaining ingredients has a synergistic effect.

The invention provides the use of mesenchymal stem cells for preparing drugs/medicines for the treatment of non-healing burn wounds. The inventor found that the mesenchymal stem cells of the present application are used to treat burn wounds and have significant curative effects. They can effectively promote the repair of hard-to-heal burn wounds, increase the healing rate of hard-to-heal burn wounds, and shorten wound healing time, with non-toxic side effects, easy absorption and other advantages. Therefore, the mesenchymal stem cells and the composition containing them can be used to prepare drugs/medicines for treating non-healing burn wounds.

The present disclosure relates to Alkynylphenylbenzamide compounds and the applications thereof. The said Alkynylphenylbenzamide compounds have the structure shown in Formula (I). The compounds can be used as protein kinase inhibitors, which can effectively inhibit the activity of TRK protein kinase and the proliferation, migration and invasion of various tumor cells. At the same time, it has the characteristics of good pharmacokinetics and low toxicity.

##STR00001##

A composition of an anti-psoriatic drug and methods of applying the anti-psoriatic drug for transdermal delivery of nanoparticles and entry into skin cells are provided. The composition of the anti-psoriatic drug includes a core having at least one gold nanoparticle, a shell of polyethylene glycol (PEG) strands conjugated to the core, and a plurality of alkyl groups conjugated to the shell of PEG strands. Moreover, a chain length of the plurality of alkyl groups, chain loading of the plurality of alkyl groups, or a diameter of the core is configured to optimize a distribution of the composition in the skin cells. The distribution may include skin permeability or an entry into keratinocytes. Further, methods of modulating effectiveness of the anti-psoriatic drug for inhibiting development of a psoriasis phenotype or for treatment of the psoriasis phenotype are provided.

Provided herein are methods and compositions for treating solid tumor cancers.

The present disclosure provides a feed additive for domesticated animals that is capable of increasing feed performance, as well as associated methods for promoting growth and zootechnical performance in domesticated animals. The animal feed additive provided contains Total Lignans standardized in the contents of Furoguaiacin-like compounds and Guaiacin-like compounds. The present disclosure also describes methods for improving growth via the dietary inclusion of Total Lignans standardized in Furoguaiacin-like compounds and Guaiacin-like compounds.

An implantable medical device is provided. The core includes a core polymer matrix within which is dispersed a therapeutic agent comprising one or more bisphosphonates. The core polymer matrix contains an ethylene vinyl acetate copolymer. The ethylene vinyl acetate copolymer has a vinyl acetate content of from about 10 wt. % to about 60 wt. % and/or a melting temperature of from about 40° C. to about 120° C. as determined in accordance with ASTM D3418-15.

Disclosed herein are advantageous drug delivery assemblies, and related methods of fabrication and use thereof. The present disclosure provides improved drug delivery assemblies for extended drug delivery (e.g., via passive diffusion) and/or tunability, and improved systems/methods for utilizing and fabricating the drug delivery assemblies. More particularly, the present disclosure provides single or dual compartment, and dual porous membrane based (e.g., porous zinc membrane based) drug delivery assemblies for extended drug delivery (e.g., via passive diffusion) and/or tunability. The present disclosure also provides for a method for utilizing a drug delivery assembly. The assemblies can be utilized for the extended drug delivery of pharmaceuticals or the like, such as biologics, for the sustained release of medication for greater than six months to overcome difficulties with daily dosing regimes.

Compositions and methods for preventing or relieving hangover symptoms are provided. The composition comprises a flavonoid such as dihydromyricetin, an antioxidant comprising a substituted pyridine, such as emoxypine succinate, and a mononucleotide such as nicotinamide mononucleotide. The composition may be administered to a subject in need thereof as an oral formulation.